利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.015 秒)

    Methods and compositions for modulating drug activity through telomere damage
    2.
    发明授权
    Methods and compositions for modulating drug activity through telomere damage 失效
    通过端粒损伤调节药物活性的方法和组合物

    公开(公告)号：US07662361B2

    公开(公告)日：2010-02-16

    申请号：US11346405

    申请日：2006-02-02

    申请人： Jessie L.-S. Au ,  M. Guillaume Wientjes

    发明人： Jessie L.-S. Au ,  M. Guillaume Wientjes

    IPC分类号： A61K49/00

    CPC分类号： A61K31/70 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.

    摘要翻译： 本发明提供了通过施用一种或多种（单独或组合）诱导端粒损伤并抑制癌细胞中的端粒酶活性的试剂来调节用于治疗癌症的治疗剂的活性的方法和组合物。 该方法最初使用例如端粒损伤诱导剂如紫杉醇和端粒酶抑制剂如AZT。 本发明还提供用于鉴定具有端粒损伤诱导活性和/或端粒酶抑制活性的其它药剂（以及具有此类活性的组合物）的方法，用于治疗癌症。

    Tumor targeting drug-loaded particles
    4.
    发明授权
    Tumor targeting drug-loaded particles 有权
    靶向药物负载粒子的肿瘤

    公开(公告)号：US08043631B2

    公开(公告)日：2011-10-25

    申请号：US11242546

    申请日：2005-10-03

    申请人： Jessie L. S. Au ,  M. Guillaume Wientjes

    发明人： Jessie L. S. Au ,  M. Guillaume Wientjes

    IPC分类号： A61K9/22 ,  A61K31/70 ,  A61K31/355

    CPC分类号： A61K9/5153 ,  A61K9/0019 ,  A61K9/0034 ,  A61K9/1647 ,  A61K9/5084 ,  A61K9/5169 ,  A61K31/337 ,  A61K31/704

    摘要： A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

    摘要翻译： 用于将肿瘤治疗剂递送给患者的组合物包括肿瘤细胞凋亡诱导剂的快速释放制剂，肿瘤治疗剂的缓释制剂和药学上可接受的载体。 药学上可接受的载体中的细胞凋亡诱导剂可以在其之前或伴随地施用。 还可以使用治疗剂（例如紫杉醇）的纳米颗粒或微粒（例如交联明胶）。 纳米颗粒或微粒可以用生物粘附剂涂层涂覆。 可以使用聚集以阻挡膀胱的淋巴管的入口以阻止微粒通过淋巴系统的清除的微球。 本发明还使用载药明胶和聚（丙交酯 - 共 - 乙交酯）（PLGA）纳米颗粒和微粒来靶向腹膜腔，膀胱组织和肾脏中的肿瘤的药物递送。

    Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
    6.
    发明授权
    Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy 失效
    确定联合治疗中使用的苏拉明的化学敏化剂量的方法和组合物

    公开(公告)号：US08580857B2

    公开(公告)日：2013-11-12

    申请号：US13031306

    申请日：2011-02-21

    申请人： Jessie L. -S. Au ,  M. Guillaume Wientjes

    发明人： Jessie L. -S. Au ,  M. Guillaume Wientjes

    IPC分类号： A61K31/17

    CPC分类号： A61K45/06 ,  A61K31/185 ,  A61K31/282 ,  A61K31/337 ,  A61K33/24 ,  A61K2300/00

    摘要： A method for determining a therapeutically effective amount of suramin for administering to a patient, who is to receive a cytotoxic agent, which comprises the steps of determining the circulating suramin concentration in the patient; administering suramin, if required, to establish a low circulating concentration of suramin in the patient of below about 200 μM; and administering the chemotherapeutic agent to the patient when the low circulating concentration of suramin is present in the patient. Conveniently a nomogram can be constructed for use in clinical settings with the suramin.

    摘要翻译： 一种用于确定用于给予接受细胞毒性剂的患者的苏拉明治疗有效量的方法，该方法包括以下步骤：确定患者中的循环苏氨胺浓度; 如果需要，施用苏拉明，在低于约200μM的患者中建立苏液敏素的低循环浓度; 并且当患者存在苏拉明的低循环浓度时，向患者施用化学治疗剂。 方便地可以构建一个列线图，用于与苏拉明的临床环境中。

    Methods and compositions for modulating cell proliferation and cell death
    8.
    发明授权
    Methods and compositions for modulating cell proliferation and cell death 失效
    调节细胞增殖和细胞死亡的方法和组合物

    公开(公告)号：US07625860B2

    公开(公告)日：2009-12-01

    申请号：US10464018

    申请日：2003-06-18

    申请人： Jessie L.-S. Au ,  M. Guillaume Wientjes

    发明人： Jessie L.-S. Au ,  M. Guillaume Wientjes

    IPC分类号： A61K38/00

    CPC分类号： C07K16/22 ,  A61K38/1825 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00

    摘要： Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and/or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation.In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.

    摘要翻译： 提供了调节FGF作用对恶性和正常细胞对抗癌剂敏感性的方法和组合物。 特别地，提供了用于在固体和软组织肿瘤，转移性损伤，白血病和淋巴瘤中抑制FGF诱导的广谱抗癌剂抗性的方法和组合物。 优选地，组合物包括与细胞毒性剂（例如抗微管剂，拓扑异构酶I抑制剂，拓扑异构酶II抑制剂，抗代谢物，有丝分裂抑制剂，烷化剂，插入剂，能够干扰信号转导途径的试剂）组合的至少一种FGF抑制剂 （例如，蛋白激酶C抑制剂，例如抗激素，例如抗生长因子受体的抗体），促进凋亡和/或坏死的药物，干扰素，白介素，肿瘤坏死因子， 和辐射。 在其他实施方案中，提供了用于保护受试者中的细胞的方法和组合物，所述方法和组合物来自例如由细胞毒性剂引起的杀伤，抑制生长或分裂或其它损伤中的一种或多种。 优选地，所述方法包括：向所述受试者施用有效量的至少一种FGF激动剂，从而治疗所述细胞，例如保护或减少所述细胞毒剂对分裂细胞的损伤。